Aeterna Zentaris aims to conduct $9.96 million at-the-market financing

H.C. Wainwright helps raise proceeds for drug development activities

By Devika Patel

Knoxville, Tenn., April 1 – Aeterna Zentaris Inc. arranged a $9.96 million at-the-market agreement for up to 3 million common shares with H.C. Wainwright & Co., LLC on April 1, according to a prospectus supplement and 8-K filed Friday with the Securities and Exchange Commission.

H.C. Wainwright will be paid a 3% commission.

Proceeds will be used for drug development activities, adding commercialized products to the company’s portfolio, general corporate purposes, working capital and to fund the company’s negative operating cash flow.

Aeterna Zentaris is a specialty biopharmaceutical company based in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.